Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06400472 · ClinicalTrials.gov registry record · Phase 1
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
A Phase 1 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 495
- Enrollment target
- 20
- Study locations
NCT06400472: Recruiting Phase 1 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms, sponsored by Eli Lilly and Company.
NCT06400472 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 495 participants, above the 320-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (55% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06400472, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 495 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Primary Outcome
Number of participants with dose-limiting toxicities (DLTs)
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG Itraconazole
- DRUG carboplatin
- DRUG bevacizumab
- DRUG LY4170156
Study Locations (20)
Other
- Cancer Research SA - Adelaide
- Icon Cancer Centre South Brisbane - QLD
- Centre Leon Berard - Lyon
- Institut de Cancerologie de l'Ouest - site St-Herblain - Saint-Herblain
- Oncopole Claudius Regaud - Toulouse
- Istituto Europeo di Oncologia - Milan
- Istituto Clinico Humanitas - Rozzano
- Shizuoka Cancer Center - Shizuoka
- National Cancer Center Hospital - Tokyo
- Cancer Institute Hospital of JFCR - Tokyo
- National Cancer Center - Goyang-si Gyeonggi-do
New York
- NYU Langone Health - Long Island - Mineola
- New York University (NYU) Clinical Cancer Center - New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center - New York
Arizona
- HonorHealth - Scottsdale
California
- University of California, San Diego (UCSD) - Moores Cancer Center - La Jolla
Michigan
- South Texas Accelerated Research Therapeutics (START) Midwest - Grand Rapids
Ohio
- The Ohio State University (OSU) Wexner Medical Center - Columbus
Texas
- The University of Texas - MD Anderson Cancer Center - Houston
Utah
- START Mountain Region - West Valley City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 495 participants |
| Start Date | 2024-05-20 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
What NCT06400472 shows while recruiting
NCT06400472 is an interventional study that assigns participants to a tested intervention. The registered 495 participants enrollment target is mid-sized for trials with a published cap, above the 320-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (55% higher).
The record links to 7 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 5 interventions - of which pembrolizumab is the first listed.
NCT06400472 names 20 study sites across 8 states, led by Other, New York, Arizona.
Frequently Asked Questions
What is clinical trial NCT06400472 about?
NCT06400472 is a clinical study titled "A Study of LY4170156 in Participants With Selected Advanced Solid Tumors". The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approx...
What is the current status of trial NCT06400472?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 495 participants. The study started on 2024-05-20. Estimated completion is 2027-04.
What conditions does trial NCT06400472 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Colorectal Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Pancreatic Neoplasm.
What interventions are being tested in trial NCT06400472?
The interventions under investigation include: pembrolizumab (DRUG), Itraconazole (DRUG), carboplatin (DRUG), bevacizumab (DRUG), LY4170156 (DRUG).
Who is sponsoring clinical trial NCT06400472?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06400472 being conducted?
This trial has 20 study locations across Arizona, California, Michigan, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06400472's enrollment target sits among peer trials
495 30th of 130 higher than 101 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase 1
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03127267 · 495 participants · Phase 3
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- NCT06417775 · 496 participants · Phase 3
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
- NCT06778447 · 496 participants · NA
Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI